Multiple myeloma patients vary widely in how they respond to treatment, but now researchers at the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences have identified a small subset of genes whose activity could predict high-risk cases and potentially guide therapy in the future.

Researchers at Emory University’s Winship Cancer Institute are the first to discover a mechanism that plays a critical role in the multiple myeloma cell cycle and survival. Their research may result in identification of a new therapeutic target for treating multiple myeloma.

Two new studies may lead to the development of more effective therapies for individuals with multiple myeloma (MM), a common and incurable blood cell cancer.

An obese person is more likely than a lean person to develop multiple myeloma, according to researchers from Brigham and Women’s Hospital, Harvard Medical School, and Harvard School of Public Health.

Moffitt clinical director part of National Myeloma Forum recommending additional studies that further evaluate new front-line oral Revlimid treatment combinations as an alternative to stem cell transplant in newly diagnosed patients

Mayo Clinic Cancer Center researchers have found that chaetocin, a by-product of a common wood mold, has promise as a new anti-myeloma agent. Results of their study, being presented today at the American Association for Cancer Research annual meeting, show the by-product to be more effective than currently used therapies at killing multiple myeloma cells. The complete findings are also available online in Blood.

Mayo Clinic Cancer Center announced today that a multiple myeloma clinical trial has shown a significant improvement in survival with lenalidomide plus low-dose dexamethasone therapy compared to lenalidomide plus high-dose dexamethasone.